Xiaosong Su

Mr. Xiaosong Su

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
JZJingbo Zou
Jingbo Zou
SZShenshen Zhi
Shenshen Zhi
MCMengyuan Chen
Mengyuan Chen
XSXingyu Su
Xingyu Su
LKLing Kang
Ling Kang
YZYueqin Zhou
Yueqin Zhou

1 December 2021 in Talanta
Verified
Journal Article
Closed access
JXJiasu Xu
Jiasu Xu
JWJin Wang
Jin Wang
XSXiaosong Su
Xiaosong Su
GQGuofu Qiu
Guofu Qiu
QZQiurong Zhong
Qiurong Zhong
NXNingshao Xia
Ningshao Xia


28 March 2020 in Micromachines
Verified
Journal Article
Open access
PDF file
XSXiaosong Su
Xiaosong Su
JZjianzhong zhang
jianzhong zhang
DZDongxu Zhang
Dongxu Zhang
YWYingbin Wang
Yingbin Wang
MCMengyuan Chen
Mengyuan Chen
NXNingshao Xia
Ningshao Xia
The shortcomings of standard plasma-separation methods limit the point-of-care application of microfluidics in clinical facilities and at the patient’s bedside. To overcome the limitations of this inconvenient, laborious, and costly technique, a new plasma-separation technique and device were developed. This new separation method relies on immunological capture and filtration to exclude cells from plasma, and is convenient, easy to use, and cost-effective. Most of the RBCs can be captured and immobilized by antibody which coated in separation matrix, and residue cells can be totally removed from the sample by a commercially plasma purification membranes. A 400 µL anti-coagulated whole blood sample with 65% hematocrit (Hct) can be separated by the device in 5 min with only one pipette. Up to 97% of the plasma can be recovered from the raw blood sample with a separation efficiency at 100%. The recovery rate of small molecule compounds, proteins, and nucleic acid biomarkers is evaluated; there are no obvious differences from the centrifuge method. The results demonstrate that this method is an excellent replacement for traditional plasma preparation protocols.

1 July 2021 in Analytica Chimica Acta
Verified
Journal Article
Closed access
JXJiasu Xu
Jiasu Xu
JWJin Wang
Jin Wang
SHShuizhen He
Shuizhen He
XSXiaosong Su
Xiaosong Su
ZZZecheng Zhong
Zecheng Zhong
NXNingshao Xia
Ningshao Xia

9 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
JXJiasu Xu
Jiasu Xu
JWJin Wang
Jin Wang
ZZZecheng Zhong
Zecheng Zhong
XSXiaosong Su
Xiaosong Su
KYKunyu Yang
Kunyu Yang
NXNingshao Xia
Ningshao Xia
A novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) emerged in late 2019, causing an outbreak of pneumonia [coronavirus disease 2019 (COVID-19)] in Wuhan, China, which then rapidly spread globally. Although the use of ready-made reaction mixes can enable more rapid PCR-based diagnosis of COVID-19, the need to transport and store these mixes at low temperatures presents challenges to already overburdened logistics networks. Here, we present an optimized freeze-drying procedure that allows SARS-CoV-2 PCR mixes to be transported and stored at ambient temperatures, without loss of activity. Additive-supplemented PCR mixes were freeze-dried. The residual moisture of the freeze-dried PCR mixes was measured by Karl-Fischer titration. We found that freeze-dried PCR mixes with ∼1.2% residual moisture are optimal for storage, transport, and reconstitution. The sensitivity, specificity, and repeatability of the freeze-dried reagents were similar to those of freshly prepared, wet reagents. The freeze-dried mixes retained activity at room temperature (18∼25°C) for 28 days, and for 14 and 10 days when stored at 37°C and 56°C, respectively. The uptake of this approach will ease logistical challenges faced by transport networks and make more cold storage space available at diagnosis and hospital laboratories. This method can also be applied to the generation of freeze-dried PCR mixes for the detection of other pathogens.